PERKINELMER INC shareholders Q3 2023

PERKINELMER INC's ticker is PKI and the CUSIP is 714046109. A total of 494 filers reported holding PERKINELMER INC in Q3 2023. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.

PERKINELMER INC shareholders Q3 2023
Name	Shares	Value	Weighting ↓
PRENTISS SMITH & CO INC	2,013	$222,839	0.16%
GLOBEFLEX CAPITAL L P	10,606	$1,174,084	0.14%
OMERS ADMINISTRATION Corp	81,654	$9,039,098	0.14%
BFSG, LLC	7,419	$821	0.13%
ExodusPoint Capital Management, LP	125,246	$13,865	0.13%
Triodos Investment Management BV	11,000	$1,217,700	0.13%
Triangle Securities Wealth Management	3,264	$361,330	0.13%
EVERENCE CAPITAL MANAGEMENT INC	13,170	$1,458	0.11%
OSTRUM ASSET MANAGEMENT	10,762	$1,191,353	0.11%
Tributary Capital Management, LLC	10,425	$1,154,047	0.11%
LEVIN CAPITAL STRATEGIES, L.P.	8,200	$907,740	0.11%
FORA Capital, LLC	10,791	$1,194,564	0.10%
Engineers Gate Manager LP	25,675	$2,842,223	0.10%
KBC Group NV	212,989	$25,301	0.10%
Lombard Odier Asset Management (Europe) Ltd	18,207	$2,015,515	0.10%
Institute for Wealth Management, LLC.	5,043	$558,261	0.10%
ARCADIA INVESTMENT MANAGEMENT CORP/MI	4,243	$469,701	0.10%
PRIMECAP MANAGEMENT CO/CA/	1,044,940	$115,674,858	0.10%
CHELSEA COUNSEL CO	1,700	$188,190	0.10%
Bayesian Capital Management, LP	7,500	$830,250	0.10%

About PERKINELMER INC

PerkinElmer Inc. is a global leader in providing innovative solutions for the life sciences and diagnostics markets. The company's products and services are used by researchers, clinicians, and laboratories around the world to improve human health and advance scientific discovery.

PerkinElmer's portfolio includes a wide range of instruments, reagents, software, and services that enable customers to detect, analyze, and interpret complex biological and chemical information. The company's offerings span the entire drug discovery and development process, from target identification and validation to clinical trials and post-market surveillance.

One of PerkinElmer's key strengths is its expertise in imaging and detection technologies. The company's instruments are used to visualize and quantify biological processes at the cellular and molecular level, providing researchers with valuable insights into disease mechanisms and potential therapeutic targets.

PerkinElmer has also made significant investments in the field of diagnostics, with a focus on developing innovative solutions for early disease detection and personalized medicine. The company's offerings in this area include genetic testing, infectious disease screening, and cancer diagnostics.

Overall, PerkinElmer is well-positioned to benefit from the growing demand for advanced technologies in the life sciences and diagnostics markets. With a strong track record of innovation and a commitment to customer service, the company is poised for continued success in the years ahead.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists PERKINELMER INC's shareholders in Q3 2023. To view PERKINELMER INC's shareholder history, click here.